Clinical Lymphology and Lymphedema
Korean Society of Lymphology and Lymphedema
REVIEW ARTICLE

림프부종환자에서 림프신티그라피에서 정상 및 비정상 소견의 임상적 의미

유민영1,*
Min Young Yoo1,*
1인하대학교 의과대학 인하대학교병원 핵의학교실
1Department of Nuclear Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Republic of Korea
*Address for correspondence: Min Young Yoo, MD, PhD, Department of Nuclear Medicine, Inha University Hospital, Inha University College of Medicine, 27, Inhang-ro, Jung-gu, Incheon 22332, Republic of Korea, Tel: +82-32-890-3174, Fax: +82-32-890-3164, E-mail: mynuclear@inha.ac.kr

ⓒ Copyright 2026 Korean Society of Lymphology and Lymphedema. This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: Oct 09, 2024; Accepted: Oct 28, 2024

Published Online: Nov 09, 2024

Abatract

Lymphoscintigraphy is a nuclear medicine imaging technique used to assess the function and structure of the lymphatic system. It plays a critical role in identifying sentinel lymph nodes prior to cancer surgery and in diagnosing lymphedema. By subcutaneously injecting radiopharmaceuticals, lymphatic flow is visualized, allowing for evaluation of lymphatic vessels and nodes with high sensitivity and specificity to detect abnormalities. In South Korea, 99mTc-phytate is the primary radiopharmaceutical used, widely applied in both the diagnosis of lymphedema and the assessment of treatment outcomes. This review discusses the principles of lymphoscintigraphy, the characteristics of radiopharmaceuticals, and the clinical relevance of normal and abnormal findings in lymphedema patients. Additionally, this review explores how lymphoscintigraphy findings vary depending on the underlying causes of lymphedema, as well as the limitations of the technique.

Keywords: Lymphoscintigraphy; Lymphedema; Radiopharmaceuticals; 99mTc-phytate; Primary Lymphedema